Accelrys Inc. to Present at Cambridge Network’s IT Special Interest Group on June 8th and at the 11th Annual Drug Discovery Leaders Summit on June 9th

SAN DIEGO, CA--(Marketwire - June 04, 2010) -

Accelrys, Inc. (NASDAQ: ACCL), a leading scientific informatics software and services company, today announced that Accelrys experts will present at two conferences the week of June 7th.

On Tuesday, June 8, 2010, Cambridge Network’s IT Special Interest Group meets to discuss ‘Cloud computing - challenges to providing bullet-proof IT services through the cloud’. At this event, which takes place at Microsoft Research, Roger Needham Building, Cambridge, UK at 6:00 pm, Conrad Agramont from Accelrys will be speaking about the company’s cloud computing strategies and how the cloud affects scientists and software makers.

On Wednesday, June 9, 2010 at 11:00 a.m., Dr. Rob Brown of Accelrys will present: “Rapid Development of Scientific Software through Pre-Competitive Industry Collaboration” at the 11th Annual Drug Discovery Leaders Summit in Montreux, Switzerland. Accelrys Biological Registration, which was released on April 20th, is the result of pre-competitive collaboration with several of the world’s leading bio-pharmaceutical companies including Abbott Laboratories and Merck & Co., Inc. By working as a Special Interest Group (SIG) with these different organizations, a comprehensive foundation for maximizing the value of biological research has been developed. Dr. Brown will feature the Biological Registration SIG as part of his talk.

Visit Accelrys events for more information.

About Accelrys, Inc.
Headquartered in San Diego, California, Accelrys develops scientific informatics software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments ‘in silico’ in order to reduce the duration and cost of discovering and developing new drugs and materials. Its scientific informatics platform underlies the company’s computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers’ proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit http://www.accelrys.com/.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: Accelrys Biologiical Registration Cloud computing Drug Discovery